JDD Webinars

Differentiating Approach to Acne Therapy: Women Vs. Men

By October 14, 2020April 22nd, 2021No Comments

Featured Article

Differentiating Approach to Acne Therapy: Women vs. Men

Join Drs. Leon H. Kircik, MD and Julie Harper, MD as they discuss Acne severity and grade (comedonal, papulopustular, mixed, nodular), skin type, presence of acne scarring and postinflammatory hyperpigmentation, menstrual cycle history (in women), and more, as well as the factors influencing treatment with classes of topical agents.

Acne vulgaris is a chronic inflammatory dermatologic disease affecting an estimated 80% of the population at some point in their life; 85% of adolescents and young adult s may experience acne and prevalent in adults with more adult women being afflicted than adult men, raising the possibility that gender difference in skin may influence the pathogenesis of acne and treatment response.
Dermatologists indicate late-onset or adult -onset acne is becoming increasingly common in women in their 20s to 50s and research shows a large number of women over age 25 have acne and the prevalence of acne remains constant until age 44 at which time there is a decrease in incidence.

FACULTY


Leon H. Kircik, MD
Clinical Professor of Dermatology
Indiana University School of Medicine
Mount Sinai Medical Center, New York, NY
Physicians Skin Care, PLLC
Louisville, KY


Julie C. Harper, MD
Clinical Associate Professor of Dermatology
University of Alabama-Birmingham
Birmingham, Alabama

Watch Now

You May Also Like

Journal of Drugs in Dermatology JDD Article about Clinical Evaluation of Thiamidol-Containing Formulations for the Visual Management of Facial Hyperpigmentation

Clinical Evaluation of Thiamidol-Containing Formulations for the Visual Management of Facial Hyperpigmentation

| Dyspigmentation, Featured Articles, Latest News | No Comments
Thiamidol shows rapid, sustained benefit for facial hyperpigmentation We’re highlighting a December 2025  article that we’re sure you’ll want to dive into! A 90‑patient randomized study found that thiamidol formulations…
Journal of Drugs in Dermatology JDD Article about Private Insurance Coverage for Botulinum Toxin for Primary Axillary Hyperhidrosis: A Cross-Sectional Analysis

Private Insurance Coverage for Botulinum Toxin for Primary Axillary Hyperhidrosis: A Cross-Sectional Analysis

| Derm Community, Featured Articles, Latest News | No Comments
Coverage clears the way: Most large private insurers pay for Botox and friends for axillary hyperhidrosis In one of our January JDD articles, we reviewed public medical‑policy guidance from the…

Year in Review: 2025 Highlights From JDD

| Featured Articles, Latest News | No Comments
Despite millennia of observation and modern understanding of HPV, treatment choices remain trade‑offs between efficacy, speed and tolerability From the Editor-in-Chief Dear Readers, As we look back on 2025, one…

Leave a Reply